B+
Bull case
20%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
TVGN
TevogenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A completed Phase 1 proof-of-concept, potential follow-on clinical development, and a possible end-2026 revenue transition could support a sharp re-rating if execution becomes visible.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical, manufacturing, regulatory, and commercialization milestones remain uncertain.
Momentum
86
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $7.00 · Bear $1.70Analysis 2026-07-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $2.00
Why
Momentum86 · Δ7d -
Value41 · Δ7d 0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Clinical, manufacturing, regulatory, and commercialization milestones remain uncertain.
- • Limited cash and expected need for additional capital, with meaningful dilution risk [#SEC-10Q-2026-05-15].
- • The latest filing shows no product revenue, continuing losses, limited cash, negative stockholders' deficit, and dependence on additional financing, making dilution and execution the dominant risks [#SEC-10Q-2026-05-15].
Catalyst clock
2026-10-14
Financing and dilution remain the key near-term risk
Lead driver: Value · See fundamentals
Momentum
86
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 86.1 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-16. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-07-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$42.85M
Beta
-0.78
Shares Out
6.51M
P/E (TTM) · Derived
-0.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.15
Rev YoY
-
EPS YoY
-0.4%
Gross Margin
-
Op Margin
-
Net Debt
$6.95M
Current Ratio
0.33
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data